Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Additionally we are shipping Tumor Necrosis Factor Receptor Superfamily, Member 11b (Osteoprotegerin) Proteins (13) and Tumor Necrosis Factor Receptor Superfamily, Member 11b (Osteoprotegerin) Kits (8) and many more products for this protein.
Showing 10 out of 49 products:
Human Monoclonal TNFRSF11B Primary Antibody for ICC, FACS - ABIN969439
Golledge, Biros, Clancy, Cooper, Palmer, Norman: A single-nucleotide polymorphism in the gene encoding osteoprotegerin is associated with diastolic blood pressure in older men. in American journal of hypertension 2009
Show all 2 references for ABIN969439
Human Monoclonal TNFRSF11B Primary Antibody for IHC, ELISA - ABIN969440
Talmud, Drenos, Shah, Shah, Palmen, Verzilli, Gaunt, Pallas, Lovering, Li, Casas, Sofat, Kumari, Rodriguez, Johnson, Newhouse, Dominiczak, Samani, Caulfield, Sever, Stanton, Shields, Padmanabhan et al.: Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. ... in American journal of human genetics 2009
Show all 2 references for ABIN969440
Dog (Canine) Polyclonal TNFRSF11B Primary Antibody for WB - ABIN2792104
Cross, Yang, Brown, Balasubramanian, Evans, Woodward, Neville-Webbe, Lippitt, Reed, Coleman, Holen: Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? in International journal of cancer. Journal international du cancer 2006
Regional variation of periosteal activity at the mandibular ramus is regulated by differential expression of osteoprotegerin.
Low-frequency vibration may promote the osteogenic differentiation capability of BMSC probably through regulating the OPG/RANKL (show TNFSF11 Antibodies) mRNA expression.
OPG (show TNFSF11 Antibodies) expression in chondrocyte increases bone mass in the proximal metaphysis of tibiae through negative regulation of osteoclast formation.
the generation of Rag2GFP+ regulatory T cells is unaltered in Tnfrsf11b(-/-) mice
identify osteoprotegerin as a HIF target gene capable of directing osteoblast-mediated osteoclastogenesis to regulate bone homeostasis
Osteoprotegerin is increased in metabolic syndrome and promotes adipose tissue proinflammatory changes.
Osteoprotegerin inhibits vascular calcification by regulating the procalcific effects of RANKL (show TNFSF11 Antibodies) and Il6 (show IL6 Antibodies) on vascular smooth muscle cells.
These results indicate that OPG (show TNFSF11 Antibodies) derived either from the bone marrow or from the vessel wall is sufficient to slow down lesion progression and vascular calcification independent of bone turnover.
High concentrations of alendronate decrease the expressions of OPG (show TNFSF11 Antibodies) and RANKL (show TNFSF11 Antibodies) in cultured osteoblasts.
In a xenograft model, increased osteoprotegerin expression correlated with a delay to pathologic fracture suggesting a potential role for mTOR (show FRAP1 Antibodies) inhibitors in the treatment of neuroblastoma (show ARHGEF16 Antibodies) bone metastases.
Data indicate in TLR4 (show TLR4 Antibodies)(-/-) mice, higher expression levels of IL-1beta (show IL1B Antibodies) and lower expression levels of VEGF (show VEGFA Antibodies), RANK, RANKL (show TNFSF11 Antibodies) and OPG (show TNFSF11 Antibodies) were detected at late time points (> postoperative 4 days).
Coptisine inhibits RANKL (show TNFSF11 Antibodies)-induced NF-kappaB (show NFKB1 Antibodies) phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL (show TNFSF11 Antibodies) and OPG (show TNFSF11 Antibodies) gene expression in osteoblastic cells.
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis (By similarity).
tumor necrosis factor receptor superfamily, member 11b
, tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)
, tumor necrosis factor receptor superfamily member 11B
, osteoclastogenesis inhibitory factor